PCK Reporter

April 19, 2013

CIPO’s Emphasis on the Problem-Solution Approach to Claim Construction Questionable in Canadian Jurisprudence

Examination Practice Respecting Purposive Construction – PN2013-02 Free World Trust and Whirlpool continue to guide the courts, with the benefit of expert testimony and cross-examination, to […]
March 28, 2013

PAB Applies Amazon.com, Finds Method for Updating Navigation Systems Installed in Vehicles Is Patentable Subject Matter

CD 1332, Re. Patent Application No. 2,195,252 entitled "System and Method for Distributing Information for Storage Media" This decision deals with a review by the Commissioner […]
March 28, 2013

PAB Confirms that under s. 47(1) It Is Not Necessary that the Invention Claimed in an Application for Reissue Relate to the Same Inventive Concept as the Issued Claims

CD 1330, Re. Patent No. 2,413,004 entitled "Self-Aligning Hitch" This recommendation deals with a review by the Commissioner of Patents of an application for reissue of […]
March 27, 2013

FC Rejects Ranbaxy’s Allegation that Astrazeneca’s Patent for Enteric Coating of Omeprazole Is Invalid for Obviousness

Astrazeneca Canada Inc. v. Ranbaxy Pharmaceuticals Canada Inc., 2013 FC 232 Astrazeneca brought an application under section 5 the PM(NOC) Regulations defending Canadian Patent No. 2,170,647 […]
March 26, 2013

Hughes J. Holds the Relevant Date for Assessing Sufficiency of a Canadian Patent Is the Date of Publication

Novartis Pharmaceuticals Canada Inc. v. Teva Canada Limited, 2013 FC 283 Novartis brought two applications under the provisions of the PM(NOC) Regulations to restrain the Minister […]
March 15, 2013

ONSC Issues Reasons for Temporarily Staying Apotex’s Damages Action against Sanofi

Apotex Inc. v. Schering Corporation, 2013 ONSC 1411 Sanofi brought a motion for an order striking Apotex’s statement of claim, or in the alternative, a stay […]
March 15, 2013

FC Holds CIPRALEX Patent Is Valid, Apotex Must Account for Profits of Infringement

Apotex Inc. v. H. Lunbeck A/S, 2013 FC 192 Apotex sought a declaration of invalidity against Lundbeck’s Canadian patent 1,339,452 (‘452) covering the serotonin reuptake inhibitor […]
March 13, 2013

Ongoing Infringement Trial Not Grounds for ex turpi causa Argument to Delay Determination of s. 8 Damages under the PM(NOC) Regulations

AstraZeneca Canada Inc. v. Apotex Inc., 2013 FCA 77 AstraZeneca appeals the trial court’s decision in a proceeding commenced by Apotex under s. 8 of the […]
March 13, 2013

FC Finds Teva’s Allegation Justified that the SEROQUEL Patent is Obvious

AstraZeneca Canada Inc. v. Teva Canada Limited, 2013 FC 245 AstraZeneca seeks an order prohibiting the Minister of Health from issuing a Notice of Compliance to […]
March 4, 2013

FC Invalidates Four of the GLEEVEC Patent Claims for Inutility Due to Lack of Sound Prediction

Teva Canada Limited v. Novartis AG, 2013 FC 141 Novartis is the owner of Canadian Patent No. 2,093,203 (the '203 Patent) covering imatinib, the active ingredient […]